HCP Plastene

Why is HCP Plastene Bulkpack Ltd falling/rising?

As of 30-Jul, HCP Plastene Bulkpack Ltd's stock price is falling to 177.00, reflecting a 3.96% decrease and underperforming its sector. The stock shows a bearish trend, trading below all major moving averages, with significantly reduced investor participation.

As of 30-Jul, HCP Plastene Bulkpack Ltd's stock price is falling, currently at 177.00, which reflects a decrease of 7.3 or 3.96%. This decline is evident in the stock's performance today, where it has underperformed its sector by 3.17%. The stock has also experienced a trend reversal, having fallen after two consecutive days of gains. <BR><BR>Intraday trading showed volatility, with the stock reaching a high of Rs 188, but it also touched a low of Rs 176, indicating significant downward pressure. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. <BR><BR>Investor participation has decreased notably, with delivery volume dropping by 84.62% compared to the 5-day average, indicating a lack of confidence among investors. Overall, these factors contribute to the stock's current decline.

Which are the latest news on HCP Plastene?

How big is HCP Plastene?

As of 10th June, HCP Plastene Bulkpack Ltd has a market capitalization of 215.00 Cr, with recent net sales of 587.51 Cr and a net profit of 23.20 Cr. The latest balance sheet shows shareholder's funds of 59.57 Cr and total assets of 260.90 Cr.

As of 10th June, HCP Plastene Bulkpack Ltd has a market capitalization of 215.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, HCP Plastene reported Net Sales of 587.51 Cr and a Net Profit of 23.20 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 59.57 Cr and Total Assets of 260.90 Cr.

Who are in the management team of HCP Plastene?

The management team of HCP Plastene includes Anil Goyel (Chairman), Prakash Parekh (Managing Director), and several Independent Directors: Meenu Maheshwari, Ashutosh Sushil Kumar Maheshvari, Sandeep M Shah, Deepti Sharma, and Judhisthir Behera, along with Krushang Shah as Company Secretary & Compliance Officer.

The management team of HCP Plastene includes the following individuals:<BR><BR>1. **Anil Goyel** - Chairman (Non-Executive)<BR>2. **Prakash Parekh** - Managing Director<BR>3. **Meenu Maheshwari** - Independent Director<BR>4. **Ashutosh Sushil Kumar Maheshvari** - Independent Director<BR>5. **Sandeep M Shah** - Independent Director<BR>6. **Krushang Shah** - Company Secretary & Compliance Officer<BR>7. **Deepti Sharma** - Independent Director<BR>8. **Judhisthir Behera** - Independent Director<BR><BR>If you have any more questions about HCP Plastene or its operations, feel free to ask!

Who are the peers of the HCP Plastene?

HCP Plastene's peers include B&B Triplewall, RDB Rasayans, Shree TirupatiBa, Aeroflex Neu, Swadeshi Inds, Mitsu Chem Plast, GLEN Industries, Worth Peripheral, and Anya Polytech. Notably, Swadeshi Inds has the highest 1-year return at 413%, while HCP Plastene's return is 17.09%.

Peers: The peers of HCP Plastene are B&B Triplewall, RDB Rasayans, Shree TirupatiBa, Aeroflex Neu, Swadeshi Inds, Mitsu Chem Plast, GLEN Industries, Worth Peripheral, and Anya Polytech.<BR><BR>Quality Snapshot: Excellent management risk is observed at RDB Rasayans and Mitsu Chem Plast, while Average management risk is found at GLEN Industries, Worth Peripheral, and the rest. Below Average management risk is noted for B&B Triplewall, Shree TirupatiBa, Aeroflex Neu, Swadeshi Inds, and Anya Polytech. In terms of Growth, Good growth is seen at Swadeshi Inds and GLEN Industries, while Below Average growth is reported for B&B Triplewall, RDB Rasayans, Shree TirupatiBa, Aeroflex Neu, Mitsu Chem Plast, Worth Peripheral, and Anya Polytech. For Capital Structure, Excellent capital structure is noted at RDB Rasayans and Worth Peripheral, while Below Average capital structure is observed at B&B Triplewall, Shree TirupatiBa, Aeroflex Neu, HCP Plastene, Mitsu Chem Plast, GLEN Industries, Anya Polytech, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Swadeshi Inds at 413.00%, while the lowest is Shree TirupatiBa at -43.25%. HCP Plastene's 1-year return of 17.09% is higher than that of RDB Rasayans, Shree TirupatiBa, and Aeroflex Neu, but lower than that of Swadeshi Inds and Mitsu Chem Plast. Additionally, GLEN Industries and Worth Peripheral have negative six-month returns.

What does HCP Plastene do?

HCP Plastene Bulkpack Ltd is a micro-cap company in the plastics packaging industry, reporting net sales of 143 Cr and a net profit of 8 Cr for the quarter ending March 2026. The company has a market cap of INR 215 Cr and key metrics include a P/E ratio of 10.00 and a dividend yield of 0.48%.

Overview: <BR>HCP Plastene Bulkpack Ltd operates in the plastics packaging industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 1984 under the name 'Gopala Polyplast Limited' and was rebranded to HCP Plastene Bulkpack Limited on September 22, 2021. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 143 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 8 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 215 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 10.00 <BR>Industry P/E: 18 <BR>Dividend Yield: 0.48% <BR>Debt-Equity: 2.81 <BR>Return on Equity: 28.47% <BR>Price to Book: 2.69 <BR><BR>Contact Details: <BR>Address: H B Jirawala House, Navbharat Soc Ushmanpura Ahmedabad Gujarat : 380013 <BR>Email: hdpeaccounts@gopalapolyplast.com <BR>Website: http://www.gopalapolyplast.com

Should I buy, sell or hold HCP Plastene Bulkpack Ltd?

When is the next results date for HCP Plastene Bulkpack Ltd?

The next results date for HCP Plastene Bulkpack Ltd is 28 May 2026.

The next results date for HCP Plastene Bulkpack Ltd is scheduled for 28 May 2026.

Are HCP Plastene Bulkpack Ltd latest results good or bad?

HCP Plastene Bulkpack Ltd's latest results show strong profit growth with a 77.27% increase in net profit and improved operating margins, but a significant 38.66% decline in net sales raises concerns about revenue sustainability and ongoing high debt levels. Overall, while profitability metrics are positive, caution is advised regarding future performance.

HCP Plastene Bulkpack Ltd's latest results present a mixed picture, but overall, there are several positive indicators. In Q3 FY26, the company reported a consolidated net profit of ₹7.02 crores, which is a significant increase of 77.27% compared to the previous quarter. Year-on-year, this represents an impressive growth of 368%, indicating a strong recovery from a low base last year.<BR><BR>However, net sales for the quarter declined by 38.66% sequentially to ₹121.27 crores, which raises concerns about revenue sustainability. Despite this drop, there was a modest year-on-year increase of 1.59%, suggesting that the previous quarter's high sales figures may have been an anomaly.<BR><BR>One of the standout aspects of the latest results is the operating margin, which improved dramatically to 15.75%, the highest in at least seven quarters. This reflects the company's ability to enhance profitability through operational efficiency rather than relying solely on sales growth. The PAT margin also rose to 6.87%, further underscoring improved profitability.<BR><BR>While the results show strong profitability metrics, the decline in sales and the high levels of debt remain areas of concern. The company's debt-to-equity ratio is notably high, which could pose risks if revenue does not stabilize.<BR><BR>In summary, while HCP Plastene's recent results indicate strong profit growth and improved margins, the significant drop in sales and ongoing debt concerns suggest a cautious outlook. The operational improvements are commendable, but sustaining this momentum will be crucial for the company's future performance.

How has been the historical performance of HCP Plastene?

HCP Plastene's historical performance has shown significant fluctuations, with net sales peaking at 11,219.74 Cr in March 2022 before declining to 463.48 Cr by March 2025, while profitability metrics have improved, turning positive in March 2025 after previous losses. Despite ongoing challenges in cash flow from operations, the company has demonstrated signs of recovery in operating profit and net profit.

Answer:<BR>The historical performance of HCP Plastene shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>HCP Plastene's net sales have varied dramatically, peaking at 11,219.74 Cr in March 2022 before declining to 463.48 Cr in March 2025. The total operating income followed a similar trend, reaching its highest at 11,219.74 Cr in March 2022 and dropping to 463.48 Cr by March 2025. Raw material costs also surged, from 13.67 Cr in March 2021 to 350.34 Cr in March 2025. Operating profit, which was negative in March 2021, improved to 39.87 Cr by March 2025, indicating a recovery despite the decline in sales. Profit before tax turned positive at 17.96 Cr in March 2025, up from a loss of 315.92 Cr in March 2022. The profit after tax showed a similar recovery, reaching 13.31 Cr in March 2025 after being negative in previous years. The consolidated net profit also turned positive at 9.63 Cr in March 2025, compared to losses in the preceding years. On the balance sheet, total liabilities increased from 48.70 Cr in March 2021 to 206.70 Cr in March 2024, while total assets rose from 48.70 Cr to 206.70 Cr in the same period. Cash flow from operating activities remained negative, indicating ongoing challenges in generating cash from core operations. Overall, HCP Plastene has shown signs of recovery in profitability metrics despite significant fluctuations in sales and costs.

Has HCP Plastene declared dividend?

HCP Plastene has declared a 10% dividend, with an ex-date of November 14, 2025. Despite the dividend declaration, the dividend yield is 0%, and total returns have varied significantly across different time periods.

HCP Plastene has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Ex-date: 14 Nov 25<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, HCP Plastene experienced a price return of 6.48%, a dividend return of 0.56%, leading to a total return of 7.04%.<BR><BR>Over the 6-month period, the company saw an impressive price return of 81.68%, with a dividend return of 0.89%, resulting in a total return of 82.57%.<BR><BR>For the 1-year period, the price return was 16.13%, the dividend return was 0.59%, culminating in a total return of 16.72%.<BR><BR>In the 2-year period, HCP Plastene had a price return of -8.34%, a dividend return of 0.48%, which resulted in a total return of -7.86%.<BR><BR>Over the 3 years, the company faced a price return of -45.96%, with a dividend return of 0.29%, leading to a total return of -45.67%.<BR><BR>In the 4-year period, HCP Plastene recorded a price return of -75.43%, a dividend return of 0.15%, resulting in a total return of -75.28%.<BR><BR>Finally, over the 5-year period, the company achieved a remarkable price return of 3031.75%, with no dividend return, leading to a total return of 3031.75%.<BR><BR>Overall, HCP Plastene has declared a dividend, but the dividend yield remains at 0%. The total returns show significant variability, with strong performance over the 5-year period contrasted by negative returns in shorter time frames.

How has been the historical performance of HCP Plastene?

HCP Plastene's historical performance shows a recovery in net sales and profitability, with net sales rising to 463.44 Cr in Mar'25 from 294.56 Cr in Mar'24, and profit after tax increasing to 13.36 Cr. However, the company faces challenges with rising liabilities and negative cash flow from operating activities.

Answer:<BR>The historical performance of HCP Plastene shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>HCP Plastene's net sales experienced a notable increase from Mar'24 at 294.56 Cr to Mar'25 at 463.44 Cr, following a dip in Mar'23 at 351.56 Cr and a dramatic decline from Mar'22's 11,219.74 Cr. Total operating income mirrored this trend, rising to 463.44 Cr in Mar'25 from 294.56 Cr in Mar'24. The raw material cost also increased significantly, reaching 350.29 Cr in Mar'25 from 212.20 Cr in Mar'24, while total expenditure rose to 428.20 Cr in Mar'25. Operating profit (PBDIT) improved to 39.92 Cr in Mar'25, up from 19.23 Cr in Mar'24, indicating a recovery from the previous years' losses. Profit before tax turned positive at 18.01 Cr in Mar'25, compared to a mere 0.20 Cr in Mar'24, and profit after tax rose to 13.36 Cr from 0.31 Cr. The consolidated net profit for Mar'25 was 9.63 Cr, a recovery from losses in the previous years. Earnings per share (EPS) also improved to 9.03 in Mar'25 from -1.12 in Mar'24. However, the company faced challenges with total liabilities increasing to 206.70 Cr in Mar'24 from 175.25 Cr in Mar'23, and total debt rising to 157.90 Cr. Cash flow from operating activities remained negative at -18.00 Cr in Mar'24, though cash flow from financing activities was positive at 23.00 Cr. Overall, HCP Plastene's financial performance indicates a recovery trend in sales and profitability, despite ongoing challenges with liabilities and cash flow.

Is HCP Plastene overvalued or undervalued?

As of October 28, 2025, HCP Plastene is considered undervalued with an attractive valuation grade, featuring a PE ratio of 14.48, an EV to EBITDA of 9.63, and a PEG ratio of 0.02, significantly outperforming peers like Garware Hi Tech and TCPL Packaging, and demonstrating a remarkable 3525.28% return over five years compared to the Sensex's 111.98%.

As of 28 October 2025, HCP Plastene's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 14.48, an EV to EBITDA of 9.63, and a PEG ratio of 0.02, which suggests significant growth potential relative to its price.<BR><BR>In the peer comparison, HCP Plastene's PE ratio is notably lower than Garware Hi Tech's 24.96 and TCPL Packaging's 22.52, both of which are classified as expensive. Additionally, AGI Greenpac, which is very attractive, has a PE ratio of 15.19, further reinforcing HCP Plastene's undervaluation. Despite a recent decline in stock price, the long-term performance shows a remarkable 3525.28% return over five years, significantly outpacing the Sensex's 111.98% return in the same period, highlighting its potential for recovery and growth.

What is the technical trend for HCP Plastene?

As of June 2, 2025, HCP Plastene's technical trend is mildly bearish, indicated by daily moving averages and monthly Bollinger Bands, despite some conflicting signals from weekly MACD and KST.

As of 2 June 2025, the technical trend for HCP Plastene has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some conflicting signals. The Bollinger Bands show a bearish trend on the monthly timeframe, which adds to the bearish outlook. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the bearish signal from the monthly Bollinger Bands.

Who are the top shareholders of the HCP Plastene?

The top shareholders of HCP Plastene include Aman Prakash Parekh with 16.86%, Bank of Baroda as the largest public shareholder at 4.8%, and individual investors holding a total of 12.81%. Additionally, foreign institutional investors hold a combined 0.07%, while mutual funds have a negligible stake.

The top shareholders of HCP Plastene include the promoters, with Aman Prakash Parekh holding the highest individual stake at 16.86%. Additionally, Bank of Baroda is the largest public shareholder, owning 4.8%. The company also has some institutional investment, with three foreign institutional investors (FIIs) holding a combined 0.07%, and mutual funds are represented by one scheme, which holds 0.0%. Individual investors collectively hold 12.81% of the shares.